Get to know our clinical trials

Phase 2b clinical trial to evaluate the safety of intralesional BO-112 in patients with primary resectable low-risk and high-risk basal cell carcinoma.

THE MAIN OBJECTIVE IS TO EVALUATE THE EFFICACY OF BO-112. ADMINISTERED BY IL INJECTION IN PATIENTS WITH PRIMARY RESECTABLE LOW-RISK OR HIGH-RISK BCC, RESPECTIVELY.

Imagen del Dr. Pedro Redondo Bellón, especialista en Dermatología Médico-Quirúrgica y Venereología de la Clínica Universidad de Navarra. El Dr. Redondo se dedica preferencialmente al cáncer de piel y a la cirugía de Mohs.
Dr. Pedro Redondo Curriculum
Codirector Dermatology Department
Madrid headquarters
Cancer Center
Skin Cancer and Melanoma Area
Status
In recruitment
headquarters
Madrid
Early phase

Technical Summary

  • MULTICENTER, PHASE 2B, OPEN-LABEL, NONRANDOMIZED, MULTICENTER CLINICAL TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF INTRALESIONAL BO-112 IN PATIENTS WITH PRIMARY RESECTABLE LOW-RISK AND HIGH-RISK BASAL CELL CARCINOMA.
  • Code EudraCT: 2024-511801-51-00
  • Protocol number: BOT-112-204
  • Promoter: HIGHLIGHT THERAPEUTICS, S.L.
  • Molecule/Drug: BO-112

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION